(Q34432186)

2 August 2017

title

Combining drug-disease and economic modelling to inform drug development decisions (English)

1 reference

2 August 2017

Bill Poland

1

1 reference

2 August 2017

Russell Wada

series ordinal

2

1 reference

2 August 2017

publication date

1 November 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

6

1 reference

2 August 2017

issue

22

1 reference

2 August 2017

page(s)

1165-1170

1 reference

Simulation of clinical trials

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902014-1

7 January 2021

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902014-1

7 January 2021

Developing compliance instructions for drug labeling

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902014-1

7 January 2021

Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902014-1

7 January 2021

Medication compliance as a feature in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902014-1

7 January 2021

10.1016/S1359-6446(01)02014-1

Identifiers

DOI

1 reference

2 August 2017

1 reference